# Ipamorelin FAQ: Common Questions Answered From the Research > Ipamorelin FAQ — direct, cited answers on what it is, the 2024 research, IGF-1, half-life, appetite, water retention, and the CJC-1295 combination. Direct answers, cited where the claim is quantitative. ## Does ipamorelin reduce belly fat? No human trial has tested ipamorelin for belly fat. The most relevant recent data come from a 2024 ferret study, where intraperitoneal ipamorelin (1-3 mg/kg) cut cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase [5] — a study about preventing weight *loss*, not reducing fat. Community reports of a gradually leaner look are anecdotal and confounded by diet and training. ## Is there new research on ipamorelin in 2024? Yes. The most recent in-vivo study, from 2024, gave ipamorelin to ferrets and found that 1-3 mg/kg intraperitoneally inhibited cisplatin-induced body-weight loss by roughly 24% in the delayed phase, with no anti-emetic effect [5]. A 2024 study of unacylated ghrelin — the same receptor family — showed protection against age-related muscle loss [11]. Several 2026 reviews then synthesized the field [12][13][14]. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and the first selective growth hormone secretagogue. In its founding characterization it released growth hormone potently in rat pituitary cells, anaesthetised rats, and conscious swine (swine ED50 2.3 nmol/kg vs 3.9 for GHRP-6), yet did not raise ACTH or cortisol even more than 200-fold above its growth-hormone ED50 [1]. It is not an approved drug. ## What does ipamorelin do for you? In research terms, ipamorelin activates the ghrelin receptor (GHS-R1a) on pituitary cells and triggers a discrete pulse of growth hormone, doing so without meaningfully raising cortisol or prolactin [1]. That is what the studies measured. Claims about what it does "for you" personally — fat loss, anti-aging — are not supported by controlled human trials; the one human efficacy trial, for bowel recovery, failed [3]. ## What is ipamorelin peptide? The ipamorelin peptide is a five-amino-acid chain (a pentapeptide) engineered for protease resistance with a non-natural amino acid at position one and two D-form residues [1]. It is derived from GHRP-1 by removing the central Ala-Trp dipeptide, and it works as a selective agonist of the ghrelin / growth hormone secretagogue receptor. It is wholly synthetic and not an endogenous human peptide. ## What are the risks of ipamorelin? The honest risk picture is dominated by missing data. The only Phase 2 RCT (114 adults, up to 7 days IV) missed its primary endpoint, with adverse events in 87.5% of the ipamorelin arm vs 94.8% of placebo — no specific signal in that short window, but no long-term human safety database [3]. Mechanistic and class-level cautions cover cancer, glucose control, and cardiovascular safety — detailed on [the effects page](/effects). ## What are the downsides of ipamorelin? The central downside is that efficacy in humans is unproven and long-term safety is uncharacterized — the one human efficacy trial failed its endpoint [3]. Commonly reported anecdotal downsides include post-injection flushing, transient appetite increase, mild water retention, and injection-site irritation, all unverified. A related-compound study also flags a class-level cardiac signal [6]. ## Why is ipamorelin being discontinued? Ipamorelin's clinical development ended because its only Phase 2 trial failed: median time to first tolerated meal was 25.3 h with ipamorelin vs 32.6 h with placebo (p=0.15), missing the primary endpoint [3]. It was never an approved product to discontinue. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access. ## What does CJC-1295 and ipamorelin do? Together they stimulate growth-hormone release through two complementary receptors — CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin receptor [1]. A 2026 narrative review found the combination improved maximal muscle tetanic tension in a glucocorticoid-induced muscle-loss model in mice, while noting the evidence is limited to animal studies [12]. No controlled human trial has tested the combination. ## Does ipamorelin increase IGF-1? Indirectly and inconsistently. Ipamorelin releases growth hormone, which drives the liver to make IGF-1, but IGF-1 was not consistently elevated in short rodent studies — a rat bone-growth study found no change in total IGF-1 despite increased bone growth [4]. In off-label human use, an observational report on combined growth hormone secretagogue therapy in hypogonadal men did find raised serum IGF-1 [16]. ## How does CJC-1295 ipamorelin work? CJC-1295 ipamorelin works by hitting two separate growth-hormone-release pathways at once: CJC-1295 supplies a sustained GHRH signal through the GHRH receptor's cAMP pathway, while ipamorelin adds a selective ghrelin-receptor pulse through calcium signaling [1]. Because the doorways are distinct and complementary, the combined pulse is larger than either alone in preclinical work [12]. ## How much CJC-1295 ipamorelin should I take? No controlled human trial has established a dose for the combination, so there is no research-grounded answer. The only human ipamorelin trial used a fixed research dose (0.03 mg/kg IV twice daily) for a hospital indication that failed [3]. Subcutaneous 'stack' regimens in forums have no peer-reviewed human dosing basis and are anecdotal — this site does not provide dosing guidance. ## Does CJC-1295 ipamorelin work? Mechanistically the combination produces a real growth-hormone effect, and a 2026 review reports it improved maximal muscle tetanic tension in a mouse model [12]. For human body-composition or anti-aging outcomes, there is no controlled-trial evidence, and the single human ipamorelin efficacy trial failed its endpoint [3]. The biology is supported; specific human outcome claims are not. ## How to reconstitute CJC-1295 ipamorelin 5mg? Ipamorelin is supplied as a lyophilized powder and reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and freeze-thaw, so solution is kept refrigerated. These are general research-supply handling notes, not a clinical preparation instruction or a direction for human use — this site provides no injection guidance. ## How long does ipamorelin stay in your system? In the one human pharmacokinetic study, the terminal half-life was about 2 hours, with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg [2]. The growth-hormone pulse it triggers peaks near 40 minutes after dosing [2]. Note that detection windows for anti-doping purposes can exceed the pharmacokinetic half-life, since assays target the molecule and its signatures. ## Does ipamorelin make you hungry? It can, mechanistically. Ipamorelin acts on the ghrelin receptor, and ghrelin-receptor agonists activate the brain's appetite centers and induce feeding in animal studies [10]. Community accounts describe an appetite uptick after injection, generally milder than with GHRP-6 — anecdotal and unverified. The effect is a recognized feature of the receptor class, not a guaranteed individual response. ## Will I gain weight on ipamorelin? There is no human trial answer. Ipamorelin showed growth-hormone-independent stimulation of adiposity in mice [9], and its ghrelin-receptor mechanism can raise appetite [10], so weight change is plausible but unmeasured in humans at research-use doses. The one human ipamorelin trial was a short perioperative study not designed to assess body weight [3]. Community reports vary and are confounded by diet and training. ## Does ipamorelin increase appetite? Yes, in mechanism and in animal data. As a ghrelin-receptor agonist, ipamorelin engages the same system the hunger hormone uses, and central ghrelin and growth hormone secretagogues induce feeding in rodents [10]. Reported real-world appetite increases are generally described as milder than with older peptides but remain an unwanted effect for some users — anecdotal and unverified. ## What does ipamorelin peptide do? The ipamorelin peptide selectively activates the ghrelin / growth hormone secretagogue receptor on pituitary cells, producing a discrete growth-hormone pulse without meaningfully raising cortisol or prolactin [1]. Downstream it can drive the IGF-1 axis, though inconsistently in short studies [4]. Beyond the pituitary, it has documented effects on pancreatic insulin release and gut motility in preclinical models [8]. ## How long does it take for ipamorelin to work? Pharmacologically, fast: the growth-hormone pulse peaks roughly 40 minutes after a dose, and the terminal half-life is about 2 hours in humans [2]. Subjective effects that users report — such as sleep changes — are typically described as appearing over one to two weeks of use, but those timelines are anecdotal and not measured in controlled trials. ## Does ipamorelin cause water retention? Possibly, by mechanism. Growth-hormone excess is associated with sodium and water retention, so raising growth-hormone pulses could promote mild fluid retention [6]. Community reports describe transient puffiness in fingers, ankles, or face in the first weeks, generally milder than with older peptides and easing with continued use — anecdotal and unverified, with no controlled human data at research-use doses. ## Where to inject CJC-1295 ipamorelin? This site provides no injection or self-administration guidance. In the published human ipamorelin studies the route was intravenous infusion under controlled conditions [2][3]; subcutaneous administration is the dominant route in off-label community use but has no published human safety or pharmacokinetic characterization. Questions about administering any unapproved peptide belong with a qualified clinician, not a research digest. --- A recent-research reading of the ipamorelin literature — the freshest 2024-2026 studies up front, the lone failed human trial and the missing long-term safety kept in plain sight, and the community reports pinned off to one side as anecdote; no telehealth, no clinic, no prescription, and nothing here dosed or dispensed.